Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ArGEN-X
ArGEN-X
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
arGEN-X and LEO Pharma sign deal to develop antibody-based treatments for skin conditions
Dutch biotechnology company could potentially receive nearly €105m in payments
Research & Development
arGEN-X awarded €1.5m grant from IWT in Flanders
To advance the application of NHance Fc modifications in therapeutic antibodies
Manufacturing
Lonza signs multi-product agreement with arGEN-X for therapeutic antibodies
Building on a four-year relationship between the two companies
Research & Development
Shire signs monoclonal antibody agreement with arGEN-X
Will make an upfront payment to arGEN-X of €15m
Research & Development
arGEN-X to collaborate with Bayer
To discover and develop therapeutic antibody candidates
Research & Development
ArGEN-X appoints Werner Lanthaler to its Supervisory Board
He has been Chief Executive of Evotec for the past five years
Research & Development
ArGEN-X appoints David Lacey to supervisory board
Former head of discovery research at Amgen joins the Dutch firm
Subscribe now